盤中異動 | 藥明生物盤中上漲5%,報於97.8港元
2021年11月9日9時47分,藥明生物(HK02269)盤中上漲5%,報於97.8港元,成交額達7.41億港元,換手率達到0.1%。
11月8日訊,11月8日南向資金今日淨賣出15.31億港元。藥明生物、美團、工商銀行分別遭淨賣出8.35億港元、7.42億港元、2.22億港元。淨買入方面,騰訊控股、海底撈、恆騰網絡分別獲淨買入10.42億港元、2.44億港元、0.82億港元。值得一提的是,南下資金已連續6日淨賣出藥明生物,共計28.0727億港元。
11月8日,瑞信:維持藥明生物(02269)“跑贏大市”評級,目標價151港元。11月5日,中泰國際:上調藥明生物(02269)目標價至143.7港元,評級升至“買入”。11月5日,大摩:予藥明生物(02269)“增持”評級,目標價175港元。
最新的財務數據顯示,公司於2021年2季度,營業收入44.07億人民幣,淨利潤18.83億人民幣;營業收入同比增加126.67%,毛利潤同比增加190.8%,淨利潤同比增加157.67%。
盈立趨勢長盈模型最近一次交易信號,2021年11月4日出現觀望信號,觸發價格爲104.8港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
![](/hk/assets/image/code.84ab0b.png)
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.